Bliss GVS Pharma informs about appointment of independent director

22 Jun 2024 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bliss GVS Pharma has informed that, subject to approval of shareholders in ensuing 39th Annual General Meeting and based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company through circular resolution approved on June 22, 2024 have appointed Nandkumar Kashinath Chodankar (DIN: 02736718) as an Additional Director in the category of Non-Executive Independent Director of the Company for a period of 5 years with effect from June 22, 2024. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are provided ‘Annexure-I’. Further, it has informed that as per the requirement of Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 with respect to Enforcement of SEBI Orders regarding Appointment of Director by Listed Companies, while considering the appointment of Nandkumar Kashinath Chodankar, have been confirmed from him that, he is not debarred from holding the office of Director pursuant to any SEBI Order or any other such authority.

The above information is a part of company’s filings submitted to BSE.

Bliss GVS Pharma Share Price

119.05 2.60 (2.23%)
11-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1687.55
Dr. Reddys Lab 1109.15
Cipla 1463.15
Lupin 1969.05
Zydus Lifesciences 868.25
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...